{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:58:03Z","timestamp":1788793083085,"version":"build-2803163510"},"reference-count":94,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)\u2010T\u2010cell therapies have reshaped the treatment of B\u2010cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches are emerging as a potential solution to address these barriers by enabling direct induction of CAR expression in T cells and other immune cells through in\u2010patient delivery of genetic constructs. This review provides an overview of the current landscape of in vivo CAR therapies. We describe the major delivery platforms under clinical development, with a focus on lentiviral vectors (LVVs) and lipid nanoparticles (LNPs), and discuss their distinct features in terms of manufacturing, mechanism of action, safety, therapeutic applications, and optimization strategies. We also summarize ongoing clinical trials exploring in vivo CAR approaches for hematologic malignancies, solid tumors, and autoimmune diseases. Finally, we highlight the key scientific and clinical challenges that remain, and examine strategies under investigation to overcome these limitations and advance in vivo CAR therapies toward broader clinical translation.<\/jats:p>","DOI":"10.1002\/hem3.70328","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:41:41Z","timestamp":1777480901000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vivo CAR therapies: Turning the patient into their own CAR factory"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3009-9601","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Vilcot","sequence":"first","affiliation":[{"name":"Laboratory of Genome Dynamics in Human Diseases, Equipe Labellis\u00e9e LIGUE 2026, Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1163, Institut Imagine Paris France"},{"name":"UNITC: French Consortium of Cell and Gene Therapies for Cancer  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole\u2010Anne","family":"Brug\u00e8re","sequence":"additional","affiliation":[{"name":"UNITC: French Consortium of Cell and Gene Therapies for Cancer  France"},{"name":"Institut Carnot CALYM Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Fuentealba","sequence":"additional","affiliation":[{"name":"UNITC: French Consortium of Cell and Gene Therapies for Cancer  France"},{"name":"CellAction, Institut Curie Saint\u2010Cloud France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"UNITC: French Consortium of Cell and Gene Therapies for Cancer  France"},{"name":"Department of Hematology University Hospital of Rennes, UMR U1236, INSERM University of Rennes Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272"},{"key":"e_1_2_14_7_1","article-title":"Advancing CAR T\u2010cell therapy: evidence\u2010based trial design for chimeric antigen receptor T\u2010cell therapy in oncology","author":"Mahat U","year":"2025","journal-title":"JAMA"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01905-1"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015013"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.019"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200980"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01933"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00245-9"},{"key":"e_1_2_14_18_1","article-title":"Universal base\u2010edited CAR7 T cells for T\u2010cell acute lymphoblastic leukemia","author":"Chiesa R","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00508-4"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02444-3"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02234-x"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01030-X"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2509522"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-LBA-1"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024523"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0285-8"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03458-w"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400209"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105834"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17060802"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.036"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0178-z"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2022.1026474"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads8473"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70062"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101148"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114056"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8470"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02512-4"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.060"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202500114"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01170-7"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501365"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trechm.2025.09.011"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.01.047"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0721"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49508-2"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-48"},{"issue":"3","key":"e_1_2_14_61_1","article-title":"In\u2010vivo CAR\u2010T cells produced by specific virus in refractory B cell lymphoma","volume":"12","author":"Chen XF","year":"2024","journal-title":"J Immunother Cancer"},{"key":"e_1_2_14_62_1","unstructured":"GrinsteinJD. First patient dosed with in vivo gene therapy for CAR T. Inside Precision Medicine. October 23 2024. Accessed December 11 2025.https:\/\/www.insideprecisionmedicine.com\/topics\/precision-medicine\/first-patient-dosed-with-in-vivo-gene-therapy-for-car-t\/"},{"key":"e_1_2_14_63_1","unstructured":"Interius BioTherapeutics Inc.Safety of INT2104 in Participants Aged 18 Years and Older Who Have B\u2010Cell Cancer That Came Back After Prior Treatment. clinicaltrials.gov;2025. Accessed December 11 2025.https:\/\/clinicaltrials.gov\/study\/NCT06539338"},{"key":"e_1_2_14_64_1","unstructured":"Umoja Biopharma.A Phase 1 Study of UB\u2010VV111 With and Without Rapamycin in Relapsed\/Refractory CD19+ B\u2010Cell Malignancies. clinicaltrials.gov;2025. Accessed December 9 2025.https:\/\/clinicaltrials.gov\/study\/NCT06528301"},{"key":"e_1_2_14_65_1","unstructured":"FanL.A Phase I Clinical Study to Evaluate the Safety Tolerability and Efficacy of the LVIVO\u2010TaVec100 Product in the Treatment of Relapsed\/Refractory B\u2010Cell Malignancies. clinicaltrials.gov;2025. Accessed December 9 2025.https:\/\/clinicaltrials.gov\/study\/NCT07002112"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148709"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2918"},{"issue":"4","key":"e_1_2_14_68_1","first-page":"1","article-title":"ASGCT 28th Annual Meeting Abstracts","volume":"33","author":"Chokshi C","year":"2025","journal-title":"Mol Ther"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02085-z"},{"key":"e_1_2_14_70_1","unstructured":"Azalea Therapeutics. Azalea Therapeutics presents new preclinical data demonstrating robust in vivo generation of TRAC\u2010CAR T cells using enveloped delivery vehicles (EDVs). GlobeNewswire News Room. November 20 2025. Accessed December 17 2025.https:\/\/www.globenewswire.com\/news-release\/2025\/11\/20\/3192000\/0\/en\/Azalea-Therapeutics-Presents-New-Preclinical-Data-Demonstrating-Robust-In-Vivo-Generation-of-TRAC-CAR-T-Cells-Using-Enveloped-Delivery-Vehicles-EDVs.html"},{"issue":"4","key":"e_1_2_14_71_1","first-page":"1","article-title":"ASGCT 28th annual meeting abstracts","volume":"33","author":"Xiao T","year":"2025","journal-title":"Mol Ther"},{"issue":"2","key":"e_1_2_14_72_1","article-title":"Preclinical development of MT\u2010303, a novel LNP\u2010formulated GPC3\u2010specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma","volume":"12","author":"Argueta S","year":"2024","journal-title":"J Immunother Cancer"},{"key":"e_1_2_14_73_1","unstructured":"Myeloid Therapeutics. Myeloid Therapeutics initiates patient dosing with MT\u2010302 a novel TROP2\u2010targeting RNA CAR in phase 1 study for advanced or metastatic epithelial tumors. Accessed December 11 2025.https:\/\/www.prnewswire.com\/news-releases\/myeloid-therapeutics-initiates-patient-dosing-with-mt-302-a-novel-trop2-targeting-rna-car-in-phase-1-study-for-advanced-or-metastatic-epithelial-tumors-301924593.html"},{"key":"e_1_2_14_74_1","unstructured":"CREATE Medicines. CREATE medicines and Amsterdam University Medical Center initiate first in vivo CAR therapy trial in frontline setting for solid tumors. Accessed December 12 2025.https:\/\/www.prnewswire.com\/news-releases\/create-medicines-and-amsterdam-university-medical-center-initiate-first-in-vivo-car-therapy-trial-in-frontline-setting-for-solid-tumors-302596696.html"},{"key":"e_1_2_14_75_1","unstructured":"CREATE Medicines. Myeloid Therapeutics rebrands as CREATE medicines focused on transforming immunotherapy through RNA\u2010based in vivo multi\u2010immune programming. Accessed December 11 2025.https:\/\/www.prnewswire.com\/news-releases\/myeloid-therapeutics-rebrands-as-create-medicines-focused-on-transforming-immunotherapy-through-rna-based-in-vivo-multi-immune-programming-302575510.html"},{"issue":"9","key":"e_1_2_14_76_1","article-title":"Effective engineering of CD8+ T cells from autoimmune disease patients utilizing a CD8\u2010targeted lipid nanoparticle encoding an anti\u2010CD19 CAR mRNA(CPTX2309)","volume":"76","author":"Zhang Y","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_14_77_1","unstructured":"Capstan Therapeutics.A First\u2010in\u2010Human Phase 1 Single\u2010Center Open\u2010Label Single and Multiple Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CPTX2309 by Intravenous Administration in Healthy Volunteers. clinicaltrials.gov;2025. Accessed December 11 2025.https:\/\/clinicaltrials.gov\/study\/NCT06917742"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-103"},{"key":"e_1_2_14_79_1","unstructured":"HuK.Open\u2010Label Single\u2010Arm Exploratory Clinical Trial to Evaluate the Safety Tolerability and Efficacy of JCXH\u2010213 in Patients With Relapsed\/Refractory B\u2010Cell Non\u2010Hodgkin Lymphoma. clinicaltrials.gov;2025. Accessed December 11 2025.https:\/\/clinicaltrials.gov\/study\/NCT06618313"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-4117"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-104"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759"},{"key":"e_1_2_14_83_1","unstructured":"Eli Lilly and Company.Lilly to acquire Orna Therapeutics to advance cell therapies. Accessed December 11 2025.https:\/\/www.prnewswire.com\/news-releases\/lilly-to-acquire-orna-therapeutics-to-advance-cell-therapies-302682157.html"},{"key":"e_1_2_14_84_1","unstructured":"Myeloid Therapeutics.Myeloid Therapeutics Initiates Patient Dosing With MT\u2010303 a Novel GPC3 Targeting RNA CAR in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC). Accessed December 11 2025.https:\/\/www.prnewswire.com\/news-releases\/myeloid-therapeutics-initiates-patient-dosing-with-mt-303-a-novel-gpc3-targeting-rna-car-in-phase-1-study-for-advanced-hepatocellular-carcinoma-hcc-302210394.html"},{"key":"e_1_2_14_85_1","unstructured":"Kelonia Therapeutics. Kelonia Therapeutics presents first\u2010in\u2010human data from phase 1 inMMyCAR study of KLN\u20101010 in vivo BCMA CAR\u2010T therapy at the American Society of Hematology (ASH) 2025 annual meeting. Accessed December 11 2025.https:\/\/www.businesswire.com\/news\/home\/20251209935959\/en\/Kelonia-Therapeutics-Presents-First-in-Human-Data-From-Phase-1-inMMyCAR-Study-of-KLN-1010-in-vivo-BCMA-CAR-T-Therapy-at-the-American-Society-of-Hematology-ASH-2025-Annual-Meeting"},{"key":"e_1_2_14_86_1","unstructured":"CREATE Medicines. CREATE medicines doses first patient in frontline HCC trial evaluating MT\u2010303 an in vivo CAR therapy in combination with standard\u2010of\u2010care immunotherapy. Accessed December 11 2025.https:\/\/www.prnewswire.com\/news-releases\/create-medicines-doses-first-patient-in-frontline-hcc-trial-evaluating-mt-303-an-in-vivo-car-therapy-in-combination-with-standard-of-care-immunotherapy-302636561.html"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00131-w"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202310078"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01245-x"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-00982-7"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6"},{"key":"e_1_2_14_94_1","article-title":"Transient hepatic reconstitution of trophic factors enhances aged immunity","author":"Friedrich MJ","year":"2025","journal-title":"Nature"},{"key":"e_1_2_14_95_1","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","author":"Costa LJ","year":"2025","journal-title":"N Engl J Med"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70328","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:08:25Z","timestamp":1780042105000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/hem3.70328"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70328","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70328"}}